False-Positive Results by the Platelia Aspergillus Galactomannan Antigen Test for Patients Treated with Amoxicillin-Clavulanate

E. Zandijk, A. Mewis, K. Magerman, and R. Cartuyvels

Department of Internal Medicine and Clinical Laboratory, Virga Jesse Hospital, Hasselt, Belgium

Received 31 December 2007/Returned for modification 11 February 2008/Accepted 28 April 2008

The Aspergillus galactomannan test is a valuable tool in the diagnosis of invasive aspergillosis. We hereby report a high rate of false-positive results by the Platelia Aspergillus galactomannan antigen test (Bio-Rad Laboratories) for patients treated with amoxicillin-clavulanate.

Invasive aspergillosis (IA) is a fungal infection with a significant morbidity and mortality, especially for neutropenic patients and stem cell transplant recipients. Early detection of IA is difficult due to a lack of sufficiently sensitive and specific diagnostic tools (4).

In recent years, tests have been developed to detect circulating fungal antigen. The Aspergillus antigen test detects galactomannan, a polysaccharide cell wall component of Aspergillus species.

False-positive results were described previously for some food products and antibiotics (2).

We report a high rate of false-positive test results by the Platelia Aspergillus galactomannan antigen test (PAG test) (Bio-Rad Laboratories, Hercules, CA) for patients treated with amoxicillin-clavulanate (AMCL).

Between 25 December 2003 and 10 February 2005, all patients staying more than 3 days on the Medical Intensive Care Unit were tested with the PAG test according to the manufacturer’s instructions. At every measurement, the patient’s medical treatment regimen was recorded. Statistical analysis was performed by the Centre for Statistics, University Hasselt, Belgium.

A total of 231 serum samples from 94 patients were tested. For 36 patients, there was only 1 measurement, while the remaining patients were tested more than once (range, 1 to 11 measurements).

For two patients, there was microbiological, clinical, or radiological evidence for IA according to the criteria of the European Organization for Research and Treatment of Cancer-Mycosis Study Group (3). These two patients (eight results) were excluded from analysis. Since all included patients were free from IA, all positive results were considered as false-positive results.

Depending on the antibiotic treatment at the moment of sampling, measurements were divided into the following four groups: (i) treatment with AMCL alone or in combination with other antibiotics, (ii) treatment with piperacillin-tazobactam (PIPTAZ) alone or in combination with other antibiotics, (iii) treatment with one or more other antibiotics, and (iv) no antibiotic treatment.

For one measurement, the patient concerned was under treatment with AMCL and PIPTAZ at the same time. Since PIPTAZ is known as a possible interfering factor for the galactomannan test, this observation was excluded (1, 10, 12).

The PAG test gives a numerical outcome that can be dichotomized as negative (<1) or positive (>1.5). This dichotomization is somewhat problematic, since there is a “gray zone” of results (≥1 and ≤1.5) for which the distinction between negative and positive is ambiguous. Therefore, two different scenarios were considered: one where the gray zone result was considered positive and one where the gray zone result was considered negative.

For each treatment group, we calculated the average test results of all measurements. To exclude the effect of differences in numbers of measurements between patients, we additionally calculated first the averages per patient within one treatment group and then the average of the patient averages (Table 1).

We also calculated false-positive rates for the two above-described scenarios (Table 2).

Results were evaluated as continuous and also as a binary version for the two above-described scenarios. The models adjusted for age and gender as possible confounding factors.

Continuous test results were analyzed by fitting a linear mixed model (i.e., a regression model with random effects). There is a significant difference between the AMCL treatment group and all three other treatment groups as follows: PIPTAZ (P < 0.0001), other antibiotics (P < 0.0001), and no antibiotics (P < 0.0001).

The binary test results were analyzed by fitting a logistic regression model with random intercept. When the gray zone was considered to be a positive result, we obtained a significantly larger false-positive rate for patients under treatment with AMCL than for the three other treatment groups: PIPTAZ (P = 0.0129), other antibiotics (P = 0.0073), and no antibiotics (P = 0.0120). When the gray zone was considered to be a negative result, we also obtained a significantly larger false-positive rate for patients under treatment with AMCL than for patients in the PIPTAZ (P = 0.0276) and other antibiotic (P = 0.0064) treatment groups.

In none of the three analyses was there a significant differ-
ence between the false-positive rates for the PIPTAZ group and the group that received other antibiotics.

Our data show that treatment with AMCL results in a proportion of false-positive results by the galactomannan test larger than that seen for the comparison groups.

The reported specificity of the Aspergillus antigen test varies between 80 and 99% (5, 6, 8, 9, 11). False-positive reactions obtained with the Pastorex Aspergillus latex agglutination test were described for food products and antibiotics, including piperacillin and AMCL (2). False-positive antigenemia caused by food products could be explained by the passage of galactomannan from the gut through the affected intestinal mucosal barrier to the circulation.

False-positive reactions for patients treated with PIPTAZ have been described previously (1, 10, 12). The results of the present study do not necessarily contradict these findings. It might be that the number of observations for the PIPTAZ treatment group was not large enough to illustrate such an effect.

Some results suggest the false-positive reactions were related to specific batches of the antibiotic (1). During the study period, several different batches of AMCL were used in our hospital. Analysis of the results did not show evidence of a time-dependent false-positive rate.

This hypothesis may be supported by the large variation in the incidence of false-positive reactions we noticed in the period after our study.

In one survey, different antibiotics, antifungals, and antivirals showed no positive results. AMCL was not tested. Only piperacillin and AMCL (2) were described for food products and antibiotics, including piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Lact. Infe. Dis. 18(9):97–108.

None 26 25 1 0 4 0
Other 109 106 0 3 3 3
PIPTAZ 25 21 1 3 16 12
AMCL 62 23 10 29 63 47

Full positive test for PIPTAZ and AMCL antigens for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematological malignancies. J. Clin. Oncol. 15:893–916.

In conclusion, treatment with AMCL can give a false-positive PAG test result. This might lead to unnecessary examinations and inappropriate treatment. When judging test results, one should bear in mind not only the clinical context but also the medication regimen at the time of sampling.

REFERENCES
1. Adam, O., A. Auperin, F. Wilquin, J. H. Bourhis, B. Gachot, and E. Chachaty. 2004. Treatment with piperacillin-tazobactam and false-positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin. Infect. Dis. 18(9):97–108.
2. Ansorg, R., R. Van den Boom, and P. M. Rath. 1997. Detection of Aspergillus antigen in foods and antibiotics. Mycosis 40:353–357.
3. Asciglio, S., J. H. Rex, B. de Pauw, J. E. Bennett, J. Bille, F. Crokaert, D. W. Denning, P. Donnelly, J. E. Edwards, Z. Erjavec, D. Fiere, O. Lortholary, J. Maertens, J. M. Meis, T. Patterson, J. Ritter, D. Selleslag, P. M. Shah, D. A. Stevens, T. J. Walsh, et al. 2002. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplant recipients: an international consensus. Clin. Infect. Dis. 34:7–14.
4. Caillot, D., O. Casasnovas, A. Bernard, J. F. Couaillier, C. Durand, B. Cuisinier, E. Solary, F. Piard, P. Trettela, A. Bonnin, G. Couillaud, M. Dumas, and H. Guy. 1997. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J. Clin. Oncol. 15:139–147.
5. Herbrecht, R., V. Letcher-Bru, C. Oprea, B. Lioure, J. Waller, F. Campus, O. Villard, K. L. Liu, S. Nataraajan-Ame, P. Lutz, P. Dufour, J. P. Bergerat, and E. Candoll. 2002. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J. Clin. Oncol. 20:1898–1906.
6. Maertens, J., J. Verhaegen, K. Lagrou, J. Van Eldere, and M. Bougaerts. 2001. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 97:1604–1613.
7. Mattei, D., D. Rappaz, N. Mordini, F. Ceda, C. Lo Nigro, M. Musso, A. Arnelli, S. Cagnassi, and A. Gallamini. 2004. False-positive Aspergillus galactomannan enzyme-linked immunosorbent assay results in vivo during amoxicillin-clavulanic acid treatment. J. Clin. Microbiol. 42:3622–3625.
8. Pinel, C., H. Fricke-Hidalgo, B. Lebeau, F. Hamidfar, P. Ambroise-Thomas, and R. Grillot. 2003. Detection of circulating Aspergillus fumigatus galactomannan: value and limits of the Platelia test for diagnosing invasive aspergillosis. J. Clin. Microbiol. 41:2184–2186.
9. Sulahian, A., F. Bourboul, P. Ribaud, T. Leblanc, C. Lacroix, and F. Derouin. 2001. Value of antigen detection using an enzyme immunoassay in the diagnosis and prediction of invasive aspergillosis in two adult and pediatric hematologic malignancies. J. Clin. Microbiol. 39:318–319.
10. Sulahian, A., S. Touratier, and P. Ribaud. 2003. False positive test for Aspergillus antigens among concomitant administration of piperacillin and tazobactam. N. Engl. J. Med. 349:2366–2367.
11. Ulusakarya, A., E. Chachaty, J. M. Vantelon, A. Youssef, C. Tancrede, J. L. Pico, J. H. Bourhis, P. Fenaux, and J. N. Munck. 2000. Surveillance of Aspergillus galactomannan antigenemia for invasive aspergillosis by enzyme-linked immunosorbent assay in neutropenic patients treated for hematologic malignancies. Hematol. J. 1:111–116.
12. Viscoli, C., M. Machetti, P. Cappellano, B. Bucci, P. Bruzzi, M. T. Van Lint, and A. Bacigalupo. 2004. False-positive galactomannan Platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin. Infect. Dis. 38:913–916.

TABLE 1. Galactomannan test result per treatment group

| Treatment group | Avg PAG test score (SD) |
|-----------------|------------------------|
|                 | General  | By patient |
| AMCL            | 2.34 (2.25) | 2.14 (2.06) |
| PIPTAZ          | 0.48 (0.59) | 0.45 (0.57) |
| Other antibiotics | 0.24 (0.43) | 0.30 (0.54) |
| No antibiotics  | 0.20 (0.20) | 0.16 (0.16) |

TABLE 2. Number of measurements and derived false-positive rates per treatment group

| Treatment | No. of measurements | % FP<sup>a</sup> with gray zone result considered: |
|-----------|---------------------|-------------------------------------------------|
|           | Total               | Negative | Gray zone | Positive | Positive | Negative |
| AMCL      | 62                  | 23       | 10        | 29       | 63       | 47       |
| PIPTAZ    | 25                  | 21       | 1         | 3        | 16       | 12       |
| Other     | 109                 | 106      | 0         | 3        | 3        | 3        |
| None      | 26                  | 25       | 0         | 1        | 0        | 4        |

<sup>a</sup> FP, false positive.